Unlike conventional CAR T cell therapy, NKG2D CAR T cells do not contain antibody fragments that recognize tumor surface antigens or protein structures that trigger the immune response, which reduces the likelihood of CAR T cell rejection by the patient’s immune system (46, 47). The gene discussed is KLRK1; the disease is neoplasm.